Linked Life Data

11557481

Source:http://linkedlifedata.com/resource/pubmed/id/11557481

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2001-9-14
pubmed:abstractText
Posaconazole is a new investigational triazole with broad-spectrum antifungal activity. The in vitro activities of posaconazole were compared with those of itraconazole and fluconazole against 3,685 isolates of Candida spp. (3,312 isolates) and C. neoformans (373 isolates) obtained from over 70 different medical centers worldwide. The MICs of the antifungal drugs were determined by broth microdilution tests performed according to the National Committee for Clinical Laboratory Standards method using RPMI 1640 as the test medium. Posaconazole was very active against all Candida spp. (MIC at which 90% of the isolates were inhibited [MIC(90)], 0.5 microg/ml; 97% of MICs were < or =1 microg/ml) and C. neoformans (MIC(90), 0.5 microg/ml; 100% of MICs were < or =1 microg/ml). Candida albicans was the most susceptible species of Candida (MIC(90), 0.06 microg/ml), and Candida glabrata was the least susceptible (MIC(90), 4 microg/ml). Posaconazole was more active than itraconazole and fluconazole against all Candida spp. and C. neoformans. These results provide further evidence for the spectrum and potency of posaconazole against a large and geographically diverse collection of clinically important fungal pathogens.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/11557481-10602757, http://linkedlifedata.com/resource/pubmed/commentcorrection/11557481-10681346, http://linkedlifedata.com/resource/pubmed/commentcorrection/11557481-10898669, http://linkedlifedata.com/resource/pubmed/commentcorrection/11557481-10970403, http://linkedlifedata.com/resource/pubmed/commentcorrection/11557481-11181372, http://linkedlifedata.com/resource/pubmed/commentcorrection/11557481-7695288, http://linkedlifedata.com/resource/pubmed/commentcorrection/11557481-8843302, http://linkedlifedata.com/resource/pubmed/commentcorrection/11557481-8980776, http://linkedlifedata.com/resource/pubmed/commentcorrection/11557481-9021172, http://linkedlifedata.com/resource/pubmed/commentcorrection/11557481-9114154, http://linkedlifedata.com/resource/pubmed/commentcorrection/11557481-9564569, http://linkedlifedata.com/resource/pubmed/commentcorrection/11557481-9738049, http://linkedlifedata.com/resource/pubmed/commentcorrection/11557481-9835520, http://linkedlifedata.com/resource/pubmed/commentcorrection/11557481-9880474
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
45
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2862-4
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
pubmed:affiliation
Department of Pathology, Medical Microbiology Division, University of Iowa College of Medicine, Iowa City, IA 52242, USA. michael-pfaller@uiowa.edu
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't